We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+50.91%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$388M
AUM Growth
-$19.7M
Cap. Flow
-$118M
Cap. Flow %
-30.34%
Top 10 Hldgs %
28.14%
Holding
181
New
33
Increased
26
Reduced
86
Closed
36

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$6.38M
2
MAZE
Maze Therapeutics
MAZE
+$5.85M
3
TERN
Terns Pharmaceuticals
TERN
+$4.05M
4
PHVS icon
Pharvaris
PHVS
+$3.91M
5
STOK icon
Stoke Therapeutics
STOK
+$3.47M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$12.9M
2
MRUS
Merus
MRUS
+$12.6M
3
ABVX
Abivax
ABVX
+$12.3M
4
SNDK
Sandisk
SNDK
+$8.63M
5
DBC icon
Invesco DB Commodity Index Tracking Fund
DBC
+$8.61M

Sector Composition

Rank Sector Weight
1 Healthcare 69.79%
2 Technology 6.85%
3 Industrials 5.94%
4 Financials 3.09%
5 Consumer Discretionary 2.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WDAY icon
76
Workday
WDAY
$44.8B
$1.39M 0.36%
6,486
-1,705
-21% -$387K
TRVI icon
77
Trevi Therapeutics
TRVI
$2.54B
$1.33M 0.34%
+106,159
New +$1.23M
CMPX icon
78
Compass Therapeutics
CMPX
$396M
$1.32M 0.34%
+245,532
New +$1.13M
TMO icon
79
Thermo Fisher Scientific
TMO
$224B
$1.31M 0.34%
+2,269
New +$1.28M
TLN
80
Talen Energy Corp
TLN
$17.1B
$1.31M 0.34%
3,488
-1,612
-32% -$627K
BKNG icon
81
Booking.com
BKNG
$160B
$1.3M 0.34%
6,075
+2,150
+55% +$442K
OFIX icon
82
Orthofix Medical
OFIX
$420M
$1.29M 0.33%
85,049
-8,151
-9% -$124K
ELVN icon
83
Enliven Therapeutics
ELVN
$4.31B
$1.27M 0.33%
82,536
-176,599
-68% -$3.52M
U icon
84
Unity
U
$19.3B
$1.27M 0.33%
28,663
-38,566
-57% -$1.57M
NAMS icon
85
NewAmsterdam Pharma
NAMS
$3.3B
$1.25M 0.32%
35,586
+3,755
+12% +$137K
RDDT icon
86
Reddit
RDDT
$30.1B
$1.22M 0.31%
5,300
-1,000
-16% -$210K
CGON icon
87
CG Oncology
CGON
$6.83B
$1.22M 0.31%
29,325
+3,285
+13% +$136K
CIEN icon
88
Ciena
CIEN
$54.9B
$1.21M 0.31%
+5,185
New +$1.01M
RBC icon
89
RBC Bearings
RBC
$17.5B
$1.21M 0.31%
2,703
-797
-23% -$338K
KBR icon
90
KBR
KBR
$4.74B
$1.21M 0.31%
30,006
-5,494
-15% -$236K
INTU icon
91
Intuit
INTU
$92B
$1.2M 0.31%
1,813
-350
-16% -$231K
APG icon
92
APi Group
APG
$18.5B
$1.18M 0.31%
30,958
-16,392
-35% -$606K
DYN icon
93
Dyne Therapeutics
DYN
$4.99B
$1.17M 0.3%
+59,643
New +$1.13M
P
94
Everpure Inc
P
$36.4B
$1.17M 0.3%
17,409
-2,991
-15% -$250K
ACHC icon
95
Acadia Healthcare
ACHC
$2.9B
$1.16M 0.3%
+81,630
New +$1.54M
GEV icon
96
GE Vernova
GEV
$269B
$1.16M 0.3%
1,768
+118
+7% +$71.9K
RXO icon
97
RXO
RXO
$3.54B
$1.15M 0.3%
90,938
+10,038
+12% +$148K
IMCR icon
98
Immunocore
IMCR
$1.74B
$1.15M 0.3%
+32,998
New +$1.16M
UTHR icon
99
United Therapeutics
UTHR
$22.1B
$1.14M 0.29%
+2,330
New +$1.09M
QXO
100
QXO Inc
QXO
$16.8B
$1.13M 0.29%
58,720
-31,480
-35% -$603K
2 3
4
5 6

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q4 2025 Portfolio in Review

As of Q4 2025, HighVista Strategies held 181 positions worth $388M, down 4.8% from $408M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies withdrew a net $118M in Q4 2025, closing 36 positions and reducing 86 holdings. Its most notable exit was Merus, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 59% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Maze Therapeutics worth $7.06M.

  • HighVista Strategies's largest Q4 2025 buy was Maze Therapeutics: 170,353 shares worth $7.06M.
  • HighVista Strategies added most to Soleno Therapeutics in Q4 2025, an estimated $6.38M increase.
  • HighVista Strategies's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $12.9M.
  • HighVista Strategies fully exited Merus in Q4 2025, selling an estimated $12.6M.
  • HighVista Strategies's ten largest holdings make up 28% of its $388M portfolio in Q4 2025.
  • HighVista Strategies opened 33 new positions and closed 36 in Q4 2025.
  • HighVista Strategies's portfolio value fell 4.8% quarter-over-quarter to $388M.

Based on HighVista Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.